LC16m8

LC16m8

A smallpox vaccine licensed for use only in Japan.
References in periodicals archive ?
As important, the LC16m8 vaccine produced minimal local reactions and no severe adverse events, said Dr.
They gave single shots of the LC16m8 vaccine--which uses a live, attenuated virus--to 3,221 participants from the Japan Self-Defense Forces between 2002 and 2005, wrote the researchers, led by Tomoya Saito of Keio University in Tokyo.
Pink Sheets: VXGN) and the Chemo-Sero Therapeutic Research Institute (Kaketsuken) of Japan announced today that they have terminated by mutual consent their agreement to co-develop a next-generation, attenuated smallpox vaccine, LC16m8, for use in the United States and elsewhere.
The LC16m8 strain had a take rate of 95% (compared with 93.
Montoya's group is comparing an investigational vaccine -- LC16m8, developed by California-based VaxGen, Inc.
PK) today announced new non-clinical data from a study of the company's attenuated smallpox vaccine candidate, LC16m8.
PK) today announced new non-clinical and clinical data from studies of the company's attenuated smallpox vaccine candidate, LC16m8, which indicate that the vaccine may represent a viable replacement for the conventional smallpox vaccine currently in the U.
Safety and Immunogenicity of Attenuated Smallpox Vaccine, LC16m8: Results from a Phase 2 Study -- Clinical Evaluation of Attenuated Smallpox Vaccine LC16m8 in Japan -- Attenuated Smallpox Vaccine LC16m8 Protects Mice from High-Dose Lethal Intranasal Ectromelia Challenge Administered 10 and 50 days Post-Vaccination -- Safety and Efficacy Study of Attenuated Smallpox Vaccine LC16m8 in Animals -- Attenuated Smallpox Vaccine LC16m8 Protects Cynomolgus Monkeys from Lethal IV Monkeypox-Zaire Challenge
Lister vaccine, the parent strain from which LC16m8 is derived, was used in the World Health Organization's successful smallpox eradication program.
PK) announced today that a study published in the September 2005 issue of the Journal of Virology(1) provides data showing that a single dose of VaxGen's smallpox vaccine candidate LC16m8 provides mice with 100% protection from vaccinia, a relative of the smallpox virus.
LC16m8 has been licensed in Japan and forms the basis of that country's strategic national stockpile of smallpox vaccine.
WHERE: Harborside Ballroom Baltimore Marriott Waterfront Hotel Baltimore, Maryland HOW: "Phase I/II Comparison of LC16m8 with Dryvax: Interim Report" (Abstract #45D) may be obtained from the ASM Biodefense website at http://www.